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OBJECTIVE — It is unclear whether the coronary atherosclerotic plaque burden is similar in
patientswithtype1andtype2diabetes.Byusingmultislicecomputedtomography(MSCT),the
presence, degree, and morphology of coronary artery disease (CAD) in patients with type 1 and
type 2 diabetes were compared.
RESEARCH DESIGN AND METHODS — Prospectively, coronary artery calcium
(CAC) scoring and MSCT coronary angiography were performed in 135 asymptomatic patients
(65 patients with type 1 diabetes and 70 patients with type 2 diabetes). The presence and extent
of coronary atherosclerosis as well as plaque phenotype were assessed and compared between
groups.
RESULTS — NodifferencewasobservedinaverageCACscore(217530vs.174361)or
in the prevalence of coronary atherosclerosis (65% vs. 71%) in patients with type 1 and type 2
diabetes.However,theprevalenceofobstructiveatherosclerosiswashigherinpatientswithtype
2diabetes(n24;34%)comparedwiththatinpatientswithtype1diabetes(n11;17%)(P
0.02). In addition, a higher mean number of atherosclerotic and obstructive plaques was ob-
served in patients with type 2 diabetes. In addition, the percentage of noncalciﬁed plaques was
higher in patients with type 2 (66%) versus type 1 diabetes (27%) (P  0.001), resulting in a
higher plaque burden for each CAC score compared with that in type 1 diabetic patients.
CONCLUSIONS — Although CAC scores and the prevalence of coronary atherosclerosis
were similar between patients with type 1 and type 2 diabetes, CAD was more extensive in the
latter. Also, a relatively higher proportion of noncalciﬁed plaques was observed in patients with
type2diabetes.Theseobservationsmaybevaluableinthedevelopmentoftargetedmanagement
strategies adapted to diabetes type.
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C
ardiovascular disease and coronary
artery disease (CAD) in particular
constitute a major cause of morbid-
ity and mortality in patients with diabetes
(1).However,managementofthispatient
population remains challenging. Current
European guidelines regard type 2 diabe-
tes as a CAD equivalent, whereas type 1
diabetes is considered a high-risk state
onlyinpresenceofmicroalbuminuria(2).
In contrast, U.S. guidelines in primary
prevention recommend stringent phar-




these guidelines are based on clinical tri-
als in patients with type 2 diabetes. How-
ever, CAD in type 1 diabetes, which has
been studied less extensively, may have a
pathophysiology distinct from that in pa-
tients with type 2 diabetes. As a result,
caution is indicated when clinical obser-
vations obtained in patients with type 2
diabetes are extrapolated to patients with
type 1 diabetes. To date, it is unclear
whetherasymptomatictype1diabeticpa-
tients beneﬁt equally from the current
preventive treatment strategies.
To optimize guidelines for type 1 di-
abetic patients, more detailed under-
standing of coronary atherosclerosis in
type1diabetesisrequired.Thusfar,most
studies have evaluated the complications
andriskfactorsassociatedwithmicrovas-
cular disease in this population (4). Stud-
ies of CAD have focused mainly on type 1
diabetic patients with kidney failure un-
dergoing coronary angiography before
kidney transplantation (5). Limited infor-
mation is available on the presence and





artery calcium (CAC) score and direct as-
sessment of coronary artery integrity. Im-
portantly, in diabetic patients the
diagnostic accuracy of MSCT coronary
angiography for the detection of signiﬁ-
cant stenoses has been shown to be simi-
lar to that for the general population (7).
In addition, the technique provides infor-
mation on atherosclerotic plaque burden
and to some extent on plaque composi-
tion (8–10). Previous studies with MSCT
revealed an increased prevalence of non-
calciﬁed coronary plaques, which have
been linked to unstable CAD, in patients
with type 2 diabetes (11,12). However,
thus far no studies have addressed plaque
morphology in patients with type 1 dia-
betes. To improve understanding of po-
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and atherosclerotic patterns as well as for
development of more targeted manage-
ment strategies, the evaluation of differ-
ences in plaque composition on MSCT
mayprovidevaluableinformation.There-
fore,thepurposeofthepresentstudywas
to explore and compare the extent, de-
gree,andmorphologyofcoronaryathero-
sclerosis by MSCT in asymptomatic
patients with type 1 and type 2 diabetes
recruited from a regular diabetes clinic.
RESEARCH DESIGN AND
METHODS— A total of 135 consecu-
tive asymptomatic patients with diabetes
were prospectively included from an on-
going registry of new patients at the dia-
betes outpatient clinic. Diabetic patients
werereferredtothecardiologyoutpatient
clinic for cardiovascular screening. Pa-
tients were stratiﬁed as having type 1 or
type2diabetesaccordingtotheAmerican
Diabetes Association criteria (13). Plasma
levels of C-peptide and autoantibodies to
islet cells, insulin, and GAD were deter-
minedtodistinguishbetweenprimaryin-
sulinopenia and immune destruction of
pancreas -cells (type 1 diabetes) and in-
sulin resistance (type 2 diabetes).
Asymptomatic status was conﬁrmed
using the Rose questionnaire for angina
(14). A structured interview, physical ex-
amination, and laboratory analysis were
obtained for all patients. Cardiovascular
riskfactorswereassessedaccordingtothe
following criteria: 1) positive family his-
tory of CAD (CAD in ﬁrst-degree family
members aged 55 (men) or 65
(women) years), 2) smoking (current
smoking or smoking in the past 2 years),
3) hypertension (blood pressure
140/90 mmHg or treatment with anti-
hypertensive medication), 4) hypercho-
lesterolemia (total cholesterol level 5.0
mmol/l or use of cholesterol-lowering
medication),5)obesity(estimatedbyBMI
[weight in kilograms divided by the
square of height in meters ]), 6) level
of glycemic control deﬁned by plasma
A1C (millimoles per liter), 7) diabetic
nephropathy (urinary albumin-to-
creatinine ratio 35 mg/mmol), and 8)
renal function (estimated by glomerular
ﬁltration rate [GFR]).
Noninvasive MSCT coronary angio-
graphy was performed in all patients as
part of a clinical protocol. Exclusion cri-
teria were ventricular and supraventricu-
lar arrhythmia and contraindications for
the use of iodinated contrast media.
MSCT data acquisition
Imaging was performed with a 64-slice
MSCTscanner(ToshibaMedicalSystems,
Tokyo, Japan). For patients with heart
rate 65 bpm, oral -blocking medica-
tion (50 or 100 mg metoprolol) was pro-
vided 1 h preceding the scan, if tolerated.
First, a prospective CAC scan without
contrast enhancement was performed,
followed by MSCT coronary angiography
according to protocols described previ-
ously (15).
Assessment of CAD by MSCT
CAC score. The CAC score was assessed
using dedicated software (Vitrea2; Vital
Images, Minnetonka, MN). CAC was
identiﬁed as a dense area in the coronary
artery exceeding the threshold of 130
Hounsﬁeld units. A total Agatston score
was determined for each patient.
Coronary atherosclerosis. All MSCT
coronary angiograms were interpreted by
two experienced observers blinded to the
patient’s characteristics. Discrepancies in
interpretation were immediately resolved
by consensus. The presence of coronary
atherosclerosis was evaluated by scrolling
through axial images, followed by visual
assessment of curved multiplanar recon-
structions in at least two orthogonal
planes. Coronary plaques were deﬁned as
structures 1m m
2 within and/or adja-
cent to the coronary artery lumen, which
could be clearly distinguished from the
vessel lumen and the surrounding peri-
cardial tissue (10).
First, the presence of any atheroscle-
rosis (1 plaque in the coronary tree) or
multivessel atherosclerosis (1 plaque in
minimum two coronary arteries) and that
of obstructive atherosclerosis (luminal
narrowing 50%) were evaluated at the
patient level in type 1 and type 2 diabetic
patients. Thereafter, a more extensive
analysis of plaque burden was obtained
by registering the total number of athero-
sclerotic plaques and obstructive plaques
foreachpatient(10).Inaddition,plaques
wereclassiﬁedaccordingtophenotype:1)
noncalciﬁed plaques (plaques with lower
density than contrast-enhanced lumen),
2) calciﬁed plaques (plaques with higher
density than contrast-enhanced lumen),
and 3) mixed plaques (plaques with
components of low- and high-density
plaques) (8–10).
Statistical analysis
Continuous variables were expressed as
means  SD and compared between the
groups of patients with type 1 and type 2
diabetes by using a two-tailed indepen-
dent t test. Categorical variables were ex-
pressed as numbers (percentages) or
medians (lower quartile, upper quartile)
and compared with a 
2 test. Separate
multivariate regression analyses with
backward elimination were performed,
correcting for all baseline clinical charac-
teristics including age, male sex, BMI,
smoking, positive family history of CAD,
hypercholesterolemia, hypertension,
A1C,GFR,andtypeofdiabetestoidentify
independent predictors of each coronary
atherosclerosis variable on MSCT.
The relationship between CAC scores
and extent of coronary atherosclerosis
was compared in patients with type 1 and
type2diabetes.Patientswerefurtherclas-
siﬁedaccordingtoCACscores:1)patients
without coronary calcium, 2) patients
with a CAC score in the range of 1–100,
and 3) patients with a CAC score 100.
The mean number of atherosclerotic le-
sions was determined for each CAC score
category.
Statistical analyses were performed
using SPSS software (version 12.0.1;
SPSS,Chicago,IL)andSASsoftware(ver-
sion 6.12; SAS Institute, Cary, NC). P 
0.05 was considered statistically
signiﬁcant.
RESULTS
Patient characteristics. A total of 135
asymptomatic diabetic patients were in-
cluded in the study. Mean age was 48 
10 years, and 79 patients (59%) were
male. The study population consisted of
65 patients with type 1 and 70 patients
with type 2 diabetes. Baseline character-
istics are provided in Table 1. Impor-
tantly, age and sex distribution were
comparable in patients with type 1 and
type 2 diabetes. However, patients with
type 2 diabetes had a signiﬁcantly higher
BMI and A1C and a shorter duration of
diagnosed diabetes. Other baseline car-
diovascularriskfactorsweresimilarinthe
two groups.




atherosclerosis were similar among pa-
tients with type 1 and type 2 diabetes.
However, the prevalence of multivessel
atherosclerosis was higher in patients
withtype2(n41;59%)thaninpatients
with type 1 (n  19; 29%) diabetes (P 
0.001). Finally, obstructive stenosis was
more prevalent in patients with type 2 di-
Coronary atherosclerosis and diabetes type
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with type 1 diabetes (n  11; 17%) (P 
0.02).
Plaque analysis. Quantiﬁcation of the
total number of atherosclerotic plaques
for each patient revealed a signiﬁcantly
highermeannumberoflesionsinpatients
with type 2 diabetes (9.9  11.9) com-
pared with that in patients with type 1
diabetes (3.4  4.8) (P  0.001) (Fig.
1A). In addition, the mean number of ob-
structive plaques was signiﬁcantly higher
in patients with type 2 diabetes (1.7 
3.9) than in patients with type 1 diabetes
(0.5  1.4) (P  0.02) (Fig. 1A).
Analysisofplaquephenotypeshowed
a higher mean number of noncalciﬁed
plaques in patients with type 2 diabetes
(6.5  9.5) versus patients with type 1
diabetes(1.01.3)(P0.001),whereas
the mean number of mixed and calciﬁed
plaques was not signiﬁcantly different.
Accordingly, a higher proportion of non-
calciﬁedplaqueswasobservedinpatients
with type 2 diabetes (66%) compared
with patients with type 1 diabetes (27%)
(P  0.001) (Fig. 1B).
Relation between type of diabetes
and the presence and extent of CAD
To correct for baseline characteristics, the
relation between type 2 diabetes (com-
pared with type 1 diabetes) and the pres-
ence and extent of CAD were evaluated
using multivariate regression analyses
(Table 3). Although type of diabetes was
not related to the presence of any athero-
sclerosis, type 2 diabetes was strongly re-
lated to the extent and degree of coronary
atherosclerosis after correction for all
other risk factors. In addition, an inde-
pendent association was observed be-
tween the presence of type 2 diabetes and
numberofnoncalciﬁedcoronaryplaques.
Relation between CAC scores and
atherosclerosis
Comparison of the CAC score versus cor-
onary angiography ﬁndings showed that
thenumberofatheroscleroticlesionspar-
alleled the increase in coronary calcium
(Fig. 1C). However, for each CAC score
category the mean number of atheroscle-
rotic lesions was signiﬁcantly higher in
patients with type 2 diabetes (Fig. 1C).
Similarly, the prevalence of obstruc-
tive atherosclerosis increased per CAC
score category (Fig. 1D). Importantly, ab-
sence of coronary calcium excluded the
presence of obstructive atherosclerosis in
patientswithtype1diabetes,whereasob-
structive atherosclerosis was identiﬁed in
three patients with type 2 diabetes (9%).
In patients with a CAC score 100, ob-
structive atherosclerosis was found in
only 2 (4%) type 1 diabetic patients,
whereas10(19%)type2diabeticpatients
showed obstructive CAD.
CONCLUSIONS — In the present
study, no signiﬁcant difference was ob-
servedintheprevalenceofatherosclerosis
in asymptomatic patients with type 1 and
type2diabetes.However,inpatientswith
type 1 diabetes, multivessel disease was
less prevalent and a lower atherosclerotic
plaque burden was observed. Moreover,
the number of obstructive coronary le-
sions was signiﬁcantly lower in patients
withtype1diabetes.Thepresenceoftype
2 diabetes (as opposed to type 1 diabetes)
was shown to be an independent predic-
tor of extent and degree of coronary ath-
erosclerosis on MSCT angiography.
Second, for each CAC score category a
higher atherosclerotic plaque burden was
observed in patients with type 2 diabetes.
This observation was explained by the
high proportion of noncalciﬁed plaques
in asymptomatic patients with type 2 di-




Most previous studies on the prevalence
of coronary atherosclerosis have used
conventionalcoronaryangiographytoex-
aminepatientswithaclinicalsuspicionof
CAD and observed more extensive CAD
in diabetic patients than in their nondia-
betic counterparts (16,17). Limited stud-
ieshavebeenperformedinasymptomatic
diabetic patients. MSCT provides accu-
rate noninvasive evaluation of the extent
and degree of coronary atherosclerosis
and may be used in patients with a lower
Table 1—Characteristics of the study population
Type 1 diabetes Type 2 diabetes P
n 65 70
Age (years) 46.0 (38.0, 54.5) 49.5 (45.0, 57.0) 0.08
Men 42 (65) 37 (53) 0.17
BMI (kg/m
2) 23.8 (22.2, 26.6) 28.2 (24.9, 33.4) 0.001
Smokers 17 (26) 14 (20) 0.40
Family history of CAD 30 (46) 37 (53) 0.44
Hypercholesterolemia 41 (63) 50 (71) 0.30
Hypertension 32 (49) 43 (61) 0.22
Duration of diabetes (years) 23.0 (9.5, 33.0) 7.5 (2.0, 13.0) 0.001
A1C (mmol/l) 7.6 (6.6, 8.6) 8.3 (7.0, 9.5) 0.04
GFR (ml/min per 1.73m
2) 101.6 (84.7, 122.8) 98.4 (81.8, 124.8) 0.88
Albuminuria* 1 (2) 4 (6) 0.20
Data are medians (lower quartile, upper quartile) or number of patients (%). n  135. *Albuminuria was
deﬁned by a urine albumin-to-creatinine ratio 35 mg/mmol.






Coronary artery calcium scores 217  530 174  361 0.59
Atherosclerosis 42 (65) 50 (71) 0.40
Atherosclerosis, multivessel 19 (29) 41 (59) 0.001
Obstructive atherosclerosis* 11 (17) 24 (34) 0.02
Plaques
No. of plaques 3.4  4.8 9.9  11.9 0.001
No. of obstructive plaques 0.5  1.4 1.7  3.9 0.02
No. of noncalciﬁed plaques 1.0  1.3 6.5  9.5 0.001
No. of mixed plaques 0.7  1.3 1.1  1.9 0.25
No. of calciﬁed plaques 1.8  3.6 2.2  3.9 0.52
Data are means  SD or number of patients (%). *Obstructive atherosclerosis was deﬁned as luminal
narrowing 50%.
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sensitivity, speciﬁcity, and negative pre-
dictive values for detection of signiﬁcant
stenosis have also been shown in diabetic
patients (7). Thus far, the technique has
beenusedinseveralstudiestoexplorethe
presence and extent of CAD in patients
with type 2 diabetes. Scholte et al. (12)
observed a high prevalence of coronary
atherosclerosis (80%), which predomi-
nantly involved more than one coronary
artery (74%), in asymptomatic type 2 di-
abetic patients. Obstructive CAD was ob-
served in 26% of patients, similar to
observations in the current study. Thus
far,noMSCTstudieshavereportedonthe
presence of CAD in asymptomatic type 1
diabetic patients.
However, using magnetic resonance
imaging, Kim et al. (6) previously evalu-
ated CAD in asymptomatic patients with
type1diabetesandobservedahigherath-
erosclerotic plaque burden in the pres-
ence of diabetic nephropathy compared
with that in normoalbuminuria. In that
particular study, an absence of diabetic
nephropathy excluded the presence of
subclinical obstructive CAD. In our cur-
rentstudy,theprevalenceofnephropathy
was low (1%) in type 1 diabetic patients,
Figure 1—A: Clustered columns demonstrating average number of lesions and obstructive lesions in type 1 (DM1) and type 2 (DM2) diabetes. A
signiﬁcantly higher mean number of lesions and obstructive lesions were observed in type 2 diabetes. B: Bar graph illustrating plaque phenotype in
type 1 and type 2 diabetes. A higher percentage of noncalciﬁed plaques was observed in type 2 diabetes. C: Clustered bar graph illustrating the
increaseinnumberoflesionsforeachCACscorecategoryamongpatientswithtype1andtype2diabetes.Theplaqueburdenwassigniﬁcantlyhigher
in type 2 diabetes for each CAC score category. D: Clustered bar graph demonstrating the increase in prevalence of obstructive atherosclerosis for
eachCACscorecategoryamongpatientswithtype1andtype2diabetes.Anabsenceofcoronarycalciumexcludedobstructiveatherosclerosisintype
1 diabetes, but not in type 2 diabetes. The prevalence of obstructive atherosclerosis was higher in type 2 diabetes for each CAC score category.
Coronary atherosclerosis and diabetes type
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atively low risk. Interestingly, however,
the absence of nephropathy did not ex-
clude subclinical obstructive CAD on
MSCT.Nevertheless,comparedwithtype
2 diabetes, the extent of atherosclerosis
was less severe with a lower prevalence of
multivessel disease and fewer lesions.
Moreover, a smaller proportion of pa-
tientswithtype1diabeteshadobstructive
atherosclerosis. Importantly, in this
study, the presence of type 2 diabetes re-
mained a signiﬁcant predictor of the se-
verity of atherosclerosis after correction
for traditional cardiovascular risk factors
including obesity, glycemic control, and
renal function. Accordingly, the higher
atherosclerotic plaque burden in patients
with type 2 diabetes may warrant more
aggressive antiatherosclerotic treatment.
On the other hand, MSCT coronary an-
giography excluded atherosclerosis in
30% of both type 1 and type 2 diabetic
patients. This ﬁnding raises the question
of whether antiatherosclerotic medical
therapy should be initiated in all asymp-
tomatic diabetic patients and to what
extent. It is possible that MSCT may be
usedtoidentifyorexcludethepresenceof
atherosclerosis and provide a basis for in-
dividually tailored therapy.
Plaque morphology and relation
with CAC
In addition to increased severity of ath-
erosclerosis, we also observed differences
in relative plaque composition in patients
with type 2 diabetes with a higher per-
centage of noncalciﬁed plaques. This
ﬁnding is in line with a previous study in
which noncalciﬁed plaques comprised
41% of atherosclerotic plaques in asymp-
tomaticpatientswithtype2diabetes(12).
In retrospective studies, a higher propor-
tion of noncalciﬁed plaques has been as-
sociated with unstable CAD. Preliminary
prognosticdataalsosuggestthatthepres-
ence of substantial noncalciﬁed plaque
indeed confers a worse outcome (18). Ac-
cordingly,ithasbeensuggestedthatthese
plaques represent more active stages of
CAD and may be more prone to rupture
(15,19). Notably, the distribution of cor-
onary plaque phenotype has not been ex-
amined previously in type 1 diabetes. In
contrast with patients with type 2 diabe-
tes, we found a higher proportion of cal-
ciﬁed plaques and a lower proportion of
noncalciﬁedplaquesinpatientswithtype
1 diabetes, despite similar CAC scores. As
a result, plaque burden was higher for
each CAC score category in type 2 com-
pared with type 1 diabetic patients.
Assessment of CAC score has been
suggested as a primary step in cardiovas-
cular risk stratiﬁcation and screening of
asymptomatic diabetic patients (20) be-
causethepresenceofelevatedCACscores
has been associated with a higher likeli-
hood of myocardial ischemia (21). How-
ever, our current observations suggest
that CAC score assessment may be more
effective in identifying CAD in patients
with type 1 diabetes. Indeed, the absence
of coronary calcium accurately excluded
the presence of obstructive coronary ath-
erosclerosis in patients with type 1 diabe-
tes.Incontrast,thisrelationwasdistorted
in patients with type 2 diabetes with a
higher prevalence of obstructive CAD in
patients without or only minor calcium.
As both the prevalence of obstructive
CADandextentofCADperCACcategory
were higher, it appears that CAC scores
may underestimate CAD in patients with
type 2 diabetes, in line with previous
comparisons with nondiabetic patients
(22). Accordingly, strategies using CAC
scores to identify diabetic patients at
higherriskshouldbedevelopedwithcau-
tion and should potentially be adjusted
for type of diabetes.
Study limitations
Several limitations need to be acknowl-
edged.Thecurrentanalysiswasrestricted
to evaluation of coronary atherosclerosis
in patients with type 1 and type 2 diabe-
tes, and the proatherogenic processes in-
volved in each form of diabetes were not
investigated. In addition, the lack of a
control group without diabetes should be
acknowledged. Because MSCT coronary
angiography involves radiation exposure,
it is not feasible to perform a similar as-
sessmentinasymptomaticsubjectsfreeof
cardiovascular risk. Furthermore, MSCT
coronary angiography requires adminis-
tration of potentially nephrotoxic con-
trast media, rendering the technique
unsuitable for use in asymptomatic dia-
betic patients with severe renal dysfunc-
tion. Finally, no follow-up data were
available. Indeed, the prognostic implica-
tions of our observations should be eval-
uated in prospective follow-up studies.
In summary, although CAC scores
and the prevalence of coronary athero-
sclerosis were similar between patients
with type 1 and type 2 diabetes, CAD was
moreextensiveinthelatter.Inaddition,a
relatively higher proportion of noncalci-
ﬁedplaqueswasobservedinpatientswith
type 2 diabetes. These observations may
be valuable in the development of tar-
geted management strategies adapted to
diabetestype.ItispossiblethatMSCTan-
giography may be useful to identify or ex-
clude the presence of atherosclerosis and
provide a basis for individually tailored
therapy.
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Table 3—Presence of type 2 diabetes (not type 1 diabetes) as a predictor of MSCT variables:
results of multivariate analysis in a backward regression model
Hazard ratio  (95% CI) P
Patients
Coronary artery calcium scores* — NS
Atherosclerosis† — NS
Atherosclerosis, multivessel† 4.16 (1.76–9.93) 0.001
Obstructive atherosclerosis†‡ 4.01 (1.38–11.60) 0.01
Plaques
No. of plaques* 6.82 (3.51–10.13) 0.001
No. of obstructive plaques* 1.40 (1.32–2.48) 0.01
No. of noncalciﬁed plaques* 6.27 (3.60–8.94) 0.001
No. of mixed plaques* — NS
No. of calciﬁed plaques* — NS
The predictive value of type 2 diabetes was tested in a separate multivariate regression model for each MSCT
variable. *Results of analysis in a multivariate linear regression model. †Results of analysis in a multivariate
binary logistic regression model. ‡Obstructive atherosclerosis was deﬁned as luminal narrowing 50%.
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